



StemCyte, Inc. located in Taiwan, US and India, is a leading global umbilical cord blood stem cell therapeutic products company. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies, and one of the largest and most ethnically diverse public cord blood banks.

StemCyte also provides service for private cord blood banking. To date, StemCyte has supplied over 1,900 cord blood units to leading transplant centers worldwide. StemCyte has developed a proprietary process which without the red cell depletion step to increase the success rate of the umbilical cord blood transplantation. StemCyte cooperates with well-known medical teams to develop regenerative therapies which show umbilical cord blood-based cell therapies are therapeutically effective in chronic stroke and spinal injuries. In cooperation with Dr. Wise Young at Rutgers university, StemCyte expects to commence phase III clinical trial of the chronic spinal injuries project this year.